Jung, Anja Gunda <br/><br/>
Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis.  [electronic resource] 

 -  Journal of the American Academy of Dermatology  Jul 2011 
 - 224-6 p.  digital 
<br/><br/> Publication Type: Case Reports; Letter 
<br/><br/><label>ISSN: </label>1097-6787 
<br/><br/><label>Standard No.: </label>10.1016/j.jaad.2009.11.034  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Absorptiometry, Photon<br/>Administration, Oral<br/>Antineoplastic Agents--administration & dosage<br/>Benzamides<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Imatinib Mesylate<br/>Mastocytosis, Systemic--complications<br/>Middle Aged<br/>Osteolysis--complications<br/>Piperazines--administration & dosage<br/>Pyrimidines--administration & dosage<br/>Risk Assessment<br/>Severity of Illness Index<br/>Treatment Outcome